MBX Biosciences to Participate in the Needham 22nd Annual Healthcare Conference
CARMEL, Ind., April 10, 2023 (GLOBE NEWSWIRE) — MBX Biosciences, Inc., a clinical stage biopharmaceutical…
CARMEL, Ind., April 10, 2023 (GLOBE NEWSWIRE) — MBX Biosciences, Inc., a clinical stage biopharmaceutical…
BOSTON, April 10, 2023 (GLOBE NEWSWIRE) — Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical…
BOSTON, April 10, 2023 (GLOBE NEWSWIRE) — Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical…
NEW YORK, April 10, 2023 (GLOBE NEWSWIRE) — Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical…
NEW YORK, April 10, 2023 (GLOBE NEWSWIRE) — Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical…
DUBLIN, Ireland, April 10, 2023 (GLOBE NEWSWIRE) — Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical…
DUBLIN, Ireland, April 10, 2023 (GLOBE NEWSWIRE) — Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical…
BERKELEY, Calif., April 10, 2023 (GLOBE NEWSWIRE) — Valitor, a biotechnology company engineering better medicines…
BERKELEY, Calif., April 10, 2023 (GLOBE NEWSWIRE) — Valitor, a biotechnology company engineering better medicines…
Shannon R. Morris, M.D., Ph.D., promoted to Chief Medical Officer Chandra D. Lovejoy promoted to…
Shannon R. Morris, M.D., Ph.D., promoted to Chief Medical Officer Chandra D. Lovejoy promoted to…
Data show that DNL343 is generally well-tolerated at doses that demonstrate robust inhibition of biomarkers…
Data show that DNL343 is generally well-tolerated at doses that demonstrate robust inhibition of biomarkers…
Phase 1b study builds on highly consistent preclinical and Phase 1a data Fort Lee, NJ,…
Phase 1b study builds on highly consistent preclinical and Phase 1a data Fort Lee, NJ,…
CHICAGO and FORT WORTH, Texas, April 10, 2023 (GLOBE NEWSWIRE) — Actuate Therapeutics, Inc. (Actuate),…
CHICAGO and FORT WORTH, Texas, April 10, 2023 (GLOBE NEWSWIRE) — Actuate Therapeutics, Inc. (Actuate),…
CANTON, Mass., April 10, 2023 (GLOBE NEWSWIRE) — Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading…
CANTON, Mass., April 10, 2023 (GLOBE NEWSWIRE) — Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading…
BOSTON, April 10, 2023 (GLOBE NEWSWIRE) — Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical…